Pacific Biosciences of California (Pacific Biosciences of California) Cash-to-Debt

: 0.68 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pacific Biosciences of California's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.68.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pacific Biosciences of California couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pacific Biosciences of California's Cash-to-Debt or its related term are showing as below:

PACB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.68 Med: 4.54 Max: 7.59
Current: 0.68

During the past 13 years, Pacific Biosciences of California's highest Cash to Debt Ratio was 7.59. The lowest was 0.68. And the median was 4.54.

PACB's Cash-to-Debt is ranked worse than
69.29% of 863 companies
in the Medical Devices & Instruments industry
Industry Median: 2.08 vs PACB: 0.68

Pacific Biosciences of California Cash-to-Debt Historical Data

The historical data trend for Pacific Biosciences of California's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.80

7.59

1.09

0.81

0.68

Pacific Biosciences of California Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.81	0.93	0.89	0.82	0.68

Competitive Comparison

For the Medical Devices subindustry, Pacific Biosciences of California's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pacific Biosciences of California Cash-to-Debt Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's Cash-to-Debt falls into.

Pacific Biosciences of California Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pacific Biosciences of California's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	631.416	/	(10.081	+	923.849)
	=	0.68

Pacific Biosciences of California's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	631.416	/	(10.081	+	923.849)
	=	0.68

Pacific Biosciences of California (NAS:PACB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pacific Biosciences of California Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

P09:Germany P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Executives

Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025